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Recombinant hirudin variant-2(Lys47), was found to be a
competitive inhibitor of human a-thrombin with respect to
peptidyl /Miitroanilide substrates. These results contrast with
those of Degryse and coworkers that suggest that recombinant
hirudin variant-2(Lys47) inhibited thrombin by a non-
competitive mechanism [Degryse et al. (1989) Protein Engng,
2,459-465]. 7-Thrombin, which can arise from a-thrombin
by autolysis, was shown to have an affinity for recombinant
hirudin variant-2(Lys47) that was four orders of magnitude
lower than that of a-thrombin. It was demonstrated that the
apparent noncompetitive mechanism observed previously was
probably caused by a contamination of the thrombin prepara-
tion by 7-thrombin. Comparison of the inhibition of a-
thrombin by recombinant hirudins variant-2(Lys47) and
variant-1, which differ from one another in eight out of 65
amino acids, indicated that the two variants have essentially
the same kinetic parameters.
Key words: hirudin/kinetics/thrombin
Introduction
Hirudin has received attention recently as a potential therapeutic
agent for the control of thrombosis (Wallis, 1988). It was
originally isolated from the medicinal leech Hirudo medicinalis
(Markwardt, 1970) and many different isoforms have been
subsequently isolated and sequenced (Bagdy et ai, 1976; Dodt
et ai, 1984, 1986; Tripier, 1988; Scharf et al., 1989). The major
form of hirudin (termed variant 1) is a polypeptide of 65 amino
acids which contains a single sulphotyrosyl residue. The
possibility of using hirudin as a therapeutic agent has evolved
with the development of systems for the recombinant expression
of hirudin (Bergmann etai, 1986; Fortkamp et al., 1986;
Harvey et al., 1986; Meyhack et al., 1987; Loison et al., 1988).
The small size of hirudin has allowed the determination of its
tertiary structure by two-dimensional NMR techniques (Clore
et al., 1987; Folkers etai, 1989; Haruyama and Wiithrich,
1989). These studies indicate that hirudin is composed of a
compact N-terminal domain (residues 3-49) held together by
three disulphide bonds, and a disordered C-terminal tail (residues
50-65). The structures of complexes between human a-thrombin
and two recombinant hirudins have also been determined recently
(Rydel etai, 1990; Griitter etai, 1990). These structures
indicate that hirudin inhibits thrombin by a novel mechanism.
Hirudin binds with its N-terminal three residues in the active-
site cleft of thrombin; the hirudin polypeptide chain runs in a
direction opposite to that expected for a substrate. In addition,
the primary specificity pocket of thrombin is not occupied by
hirudin. The C-terminal tail of hirudin wraps around the putative
fibrinogen secondary binding site.
The kinetics of inhibition of thrombin by hirudin have been
studied by a number of groups and the results obtained are not
entirely consistent between studies (Fenton etai, 1979;
Walsmann and Markwardt, 1981; Stone and Hofsteenge, 1986;
Braun etai, 1988a; Dodt etai, 1988, 1990; Degryse et ai,
1989). Although all studies indicate that hirudin is an extremely
tight-binding inhibitor of thrombin, estimates of the dissociation
constant of the thrombin-hirudin complex have varied by over
three orders of magnitude (Walsmann and Markwardt, 1981;
Stone and Hofsteenge, 1986). The discrepancies between the
various values for the dissociation constants can be explained at
least in part by the use of different reaction conditions and
different forms of hirudin and thrombin. For example, the
dissociation constant for the thrombin—hirudin complex has been
shown to be strongly dependent on ionic strength (Stone and
Hofsteenge, 1986; Stone etai, 1989). The post-translational
modification of Tyr63 to form sulphotyrosine does not occur in
any of the expression systems so far used and this lack of a
sulphate group leads to a lower affinity of human a-thrombin
for the recombinant molecule (Braun et al., 1988a; Dodt et ai,
1988, 1990). The affinity of human thrombin for hirudin is higher
than that of bovine thrombin (Dodt et al., 1990). Proteolytically
degraded forms of human thrombin have a lower affinity for
hirudin (Landis et ai, 1978; Stone etai, 1987).
Different mechanisms of inhibition have been suggested also
by different workers. While the results of Stone and Hofsteenge
(1986) indicate that hirudin variant-1 inhibits thrombin by a
competitive mechanism, Degryse et al. (1989) have suggested
that a noncompetitive mechanism applies to recombinant hirudin
variant-2 with the mutation Asn47—Lys (rHV2-Lys471). This
difference in the kinetic mechanism could be due to the different
forms of hirudin used or to the different assay conditions in the
two studies.
This paper attempts to determine the basis for the observed
difference in kinetic mechanism. Moreover, we have determined
the kinetic constants for rHV2-Lys47 and recombinant hirudin
variant-1 (rHVl) under identical conditions and, thus, have been
able to evaluate to what extent the previous discrepancies in values
of dissociation constants were due to differences in forms of
hirudin used.
Materials and methods
Materials
The substances D-Phe-pipecolyl-Arg-p-nitroanilide (D-Phe-Pip-
Arg-pNA; S-2238) and D-Val-Leu-Arg-/?-nitroanilide (D-Val-Leu-
Arg-pNA; S-2266) were from Kabi (Molndal, Sweden) whereas
tosyl-Gly-Pro-Lys-p-nitroanilide (tos-Gly-Pro-Arg-pNA;
Chromozym-PL) was from Boehringer-Mannheim, FRG). r-
HV2-Lys47 was purchased from Pentapharm (Basel,
Switzerland) and rHVl was a gift from Ciba-Geigy (Basel,
Switzerland). Human a-thrombin and 7-thrombin were prepared
as described previously (Stone and Hofsteenge, 1986; Braun
et al., 1988b) and were fully active as determined by active site
titration with 4-methylumbelliferyl /j-guanidinobenzoate (Jameson
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et al., 1973). Amino acid sequence analysis (Hewick et al., 1981)
and polyacrylamide gel electrophoresis (Laemmli, 1970) indicated
that the a-thrombin used was pure and free from degraded forms.
In addition, human a-thrombin was obtained from Sigma (St
Louis, MO). PAGE (Laemmli, 1970), followed by densiometric
scanning of this thrombin preparation (4200 NIH units/mg;
Catalogue no. T6759; Lot 114F-9461), indicated that it contained
a substantial amount (>20%) of degraded forms of thrombin
/3 and y.
Amidolytic assay of thrombin
Assays were performed at 37°C in buffers containing 0.1%
poly(ethylene glycol) Mr 6000 as previously described (Stone
and Hofsteenge, 1986). Three different buffer systems were used.
Buffer 1 consisted of 0.05 M Tris-HCl buffer, pH 7.8,
containing 0.1 M NaCl. An ionic strength of 0.125 M can be
calculated for this buffer (Ellis and Morrison, 1982). Buffer 2
was the buffer used by Degryse et al. (1989) and contained
0.05 M piperazine-N',N-bis-2-ethanesulphonic acid (PIPES) -
NaOH, pH 7.9, and 0.18 M NaCl with a calculated ionic strength
of 0.327 M. Buffer 3 consisted of 0.05 M Tris-HCl, pH 7.8
and 0.3 M NaCl and had an ionic strength of 0.325 M. The type
and concentration of substrate used and the concentration of
thrombin varied between the experiments.
Data analysis
Determination of the concentrations of the hirudin variants. The
concentration of active hirudin molecules was determined by
titration of 1.0 nM thrombin in Buffer 1 containing 200 /*M D-
Val-Leu-Arg-pNA. The dependence of the steady-state velocity
on the amount of hirudin present in the assay could be described
by equation (1) (Stone and Hofsteenge, 1986):
2£, CD
where vs is the observed steady-state velocity, VQ is the steady-
state velocity in the absence of hirudin, Et is the total molar
enzyme concentration, Kv is the apparent inhibition constant, Ia
is /tl/ml of hirudin added and a is the molar concentration of
1.0 jd/ml of hirudin. Analysis of the data yielded values for a
that could be used to calculate the concentrations of hirudin in
the stock solutions.
Determination of kinetic parameters. The inhibition of thrombin
by hirudin can be represented by the following scheme:
thrombin + hirudin' thrombin—hirudin
The dissociation constant (K{) for the thrombin —hirudin
complex can be related to the association (k{) and dissociation
(k2) rate constants by the expression K\ = k2lk\. The kinetic
parameters for the inhibition of human a-thrombin by
rHV2-Lys47 and rHVl were determined under several different
experimental conditions. Under all conditions used, hirudin acted
as a slow, tight-binding inhibitor of thrombin and the data were
fitted to equation 4 of Stone and Hofsteenge (1986) by nonlinear
regression. These analyses yielded values for the apparent
dissociation constant (Kv) and apparent association rate constant
(kv). With the substrate tos-Gly-Pro-Lys-pNA, a background
rate of hydrolysis was observed in the absence of enzyme. This
rate was dependent on the substrate concentration and equal to
0.035 ^M/min/mM substrate. The data were corrected for this
background rate before analysis. The rate of hydrolysis of D-
Phe-Pip-Arg-pNA in the absence of thrombin was negligible.
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The dependence of the value of Kv on the concentration of
substrate for a competitive inhibitor is given by equation 2:
Kv = S/KJ (2)
where S is the substrate concentration and Km is its Michaelis
constant. This equation can be used to calculate K\ from the
observed value of Kv.
Stimulation of the effect of contamination by y-thrombin. It has
been shown previously that hirudin has a much lower affinity
for human 7-thrombin than for a-thrombin (Landis et al., 1978;
Stone et al., 1987). The effect of contamination by 7-thrombin
was simulated according to equation 3:
V, = + vs. (3)
where vsa and vSy are the contributions to the observed velocity
(vs) made by the a- and 7-thrombin in the preparation
respectively. The values of vsa and vS7 are given by:
= TT l[*iy + A -
4ATIa.£J14 - - Ea)\ (4)
A -
where Ea and Ey are the concentrations of a- and 7-thrombin
respectively, and Kia' and K^ are the apparent dissociation
constants for hirudin with a- and 7-thrombin. The values Kw
and Kly. for these simulations can be calculated at different
substrate concentrations by using equation (2). Estimates for
Kla, Kly and the Km values for a- and 7-thrombin with the
substrate are required for these calculations. The values of Km
to be used in these calculations were determined as described
by Hofsteenge et al. (1986) to be 105 ± 9 /tM and 98 ± 2 ^M
for the substrate tos-Gly-Pro-Lys-pNA with a- and 7-thrombin
respectively. The value of the Kia was determined to be 2.3 pM
(Table I) under the conditions used by Degryse et al. (1989).
The value of Kly was determined from the observed inhibition
of 7-thrombin by rHV2-Lys47 under the same conditions. The
data were fitted to the Dixon equation (Segel, 1975) and a value
of 75 ± 3 nM for K]y was calculated after correcting for the
concentration of substrate according to equation (2).
Using the above constants, values for K\a' and Kly> were
calculated at a number of different substrate concentrations and
inhibition data were simulated with different ratios of a- to 7-
thrombin under the conditions similar to those used by Degryse
et al. (1989): the total enzyme concentration was maintained at
4.5 nM and the concentration of rHV2-Lys47 was varied from
0 to 6 nM (10 points). For each substrate concentration, 10 sets
of data were simulated according to equation 3. A normally
distributed random error with a standard deviation of 2% of the
theoretical value was introduced into the simulated data (Pollard,
1977). The 10 sets of simulated data were analysed according
to equation (1) with Ex = Ea + Ey and 10 estimates for Kv were
obtained. The weighted mean estimate of Kr was calculated for
each substrate concentration.
Results
The hirudin variant rHV2-Lys47 is a competitive inhibitor of
human a-thrombin
The kinetic mechanism of the inhibition of human a-thrombin
by rHV2-Lys47 was studied under the conditions used by
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Table I. Kinetic parameters for the interaction of rHV2-Lys47 and rHV 1
with human a-thrombin
0.0 0.5 1.0 1.5
[tos-Gly-Pro-Lys-pNA] (inM)
Fig. 1. Dependence of the apparent dissociation constant (Ky) for
rHV2-Lys on the concentration of the substrate tos-Gly-Pro-Lys-pNA.
Assays were performed in PIPES-NaOH buffer (Buffer 2) and the data
analysed as described in Materials and methods to yield estimates for Ky at
the indicated substrate concentrations. These estimates were weighted
according to the squared inverse of their standard errors and fitted to
equation 2. The line drawn depicts the result of this fitting. For this
analysis, the value of Km in equation (2) was fixed at the previously
determined value of 105 /iM.
Degryse et al. (1989), i.e. in PIPES-NaOH buffer (pH 7.9) with
an ionic strength of 0.33 M (Buffer 2) with the substrate tos-
Gly-Pro-Lys-pNA. Values for the apparent dissociation constant
(Ky) were determined at a particular substrate concentration by
varying the concentration of rHV2-Lys47 from 56 to 280 pM
with a fixed concentration of 200 pM a-thrombin. Under these
conditions, rHV2-Lys47 acted as a slow, tight-binding inhibitor
(data not shown) and analysis of progress-curve data yielded
values for Kv and for the apparent association rate constant (kv).
The values of Ky showed a linear dependence on the
concentration of the substrate as would be expected from equation
(2) for a competitive inhibitor (Figure 1). A value of 105 ± 9
fiM was determined for the Km of tos-Gly-Pro-Lys-pNA from
initial-velocity studies. The value of Km in equation (2) was
fixed at this value and the data of Figure 1 fitted by weighted
linear regression to this equation. The line drawn in Figure 1
represents the result of this analysis and it can be seen that the
data fit well to the equation describing competitive inhibition.
The value for Kt obtained from this analysis was 2.29 ±
0.05 pM (Table I).
The estimate of Jt|- did not vary greatly over the substrate
range tested. Similar results were obtained previously with native
hirudin variant-1 (Stone and Hofsteenge, 1986). The weighted
average of the six determinations of ky was (3.6 ± 0.1) x 107/
M/s and it can be assumed that this value approximates the true
value of the association rate constant fc| (Table I).
In order to confirm the competitive nature of the inhibition
by rHV2-Lys47, the substrate-dependence of the value of Ky was
determined with another substrate. The results obtained with the
substrate D-Phe-Pip-Arg-pNA are shown in Figure 2; a similar
linear dependence was observed. The concentrations of a-
thrombin and rHV2-Lys47 used to obtain the data presented in
Figure 2 were also different; the enzyme was present at a
concentration of 20 pM while rHV2-Lys47 was varied from 61
to 306 pM. An estimate of 4.2 ± 0.2 /xM was determined from
initial-velocity studies for the Km of D-Phe-Pip-Arg-pNA in the
PIPES-NaOH buffer used and the value of Km in equation (2)
was fixed at this value for the analysis of the data of Figure 2.
Experimental conditions Kinetic parameters
Buffer Substrate t, x 10"
(/m/s) (pM)
rHV2-Lys47
PIPES-NaOH" tos-Gly-Pro-Lys-pNA 3.61 ± 0.07 2.29 ± 0.05
(/ = 0.33 M)
PIPES-NaOHb D-Phe-Pip-Arg-pNA 2.78 ± 0.03 2 35 ± 0.02
(/ = 0 33 M)
Tris-HClc D-Phe-Pip-Arg-pNA 2.51 ±0 .11 2.47 ± 0 . 0 4
(/ = 0.33 M)
Tris-HCl D-Phe-Pip-Arg-pNA 11.3 ± 0.64 0.364 ± 0.015
(/ = 0.125 M)
rHVl
Tris-HCl D-Phe-Pip-Arg-pNA 3.25 ± 0.16 0.991 ± 0.030
(/ = 0 33 M)
Tris-HCld D-Phe-Pip-Arg-pNA 13.7 ± 0.3 0.231 ± 0.006
(/ = 0.125 M)
Values of Kt and kt were calculated from apparent values as described in
the text. The Km values for D-Phe-Pip-Arg-pNA that were used in the
calculations were 3 6, 4.2 and 3 0 pM for Buffers 1, 2 and 3 respectively.
aThese values were calculated from the data of Figure 1.
*These values were calculated from the data of Figure 2.
cThese values represent the weighted mean of two determinations.
dFrom Braun et al. (1988a).
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Fig. 2. Dependence of the apparent dissociation constant (Kv) for
rHV2-Lys4' on the concentration of the substrate D-Phe-Pip-Arg-pNA.
Assays were performed in PIPES-NaOH buffer (Buffer 2) and the data
analysed as described in Materials and methods to yield estimates for Ky at
different substrate concentrations. These estimates were fitted by weighted
linear regression to equation 2 as described in the legend to Figure 1 with
the value of Km set at 4.2 /tM The line drawn depicts the fit of the data to
equation (2).
This analysis yielded a value of 2.35 ± 0.02 pM for K{. The
good fit of the data to equation (2) shown in Figure 2 indicates
that the competitive model, which this equation describes, is an
appropriate one for the interaction of rHV2-Lys47 with a-
thrombin. Moreover, the good agreement between the values for
K{ estimated from the data of Figures 1 and 2 confirms this
competitive model.
As was observed with the substrate tos-Gly-Pro-Lys-pNA, the
value of lci * did not vary with the concentration of D-Phe-Pip-
Arg-pNA and the value for k\ given in Table I represents the
weighted mean of the eight determinations of ky.
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Comparison of the inhibitory properties of the hirudin
variants rHVl and rHV2-Lys4?
For the comparison of the inhibitory properties of rHV2-Lys47
and rHVl, Tris-HCl buffers have been used. [PIPES-NaOH
buffer was used in the above studies so that the results would
100 200 300 400 500 600
0 100 200 300 400 500 600
[tos-Gly-Pro-Lys-pNA] 0*M)
Fig. 3. Dependence of the apparent dissociation constant {Kv) for
rHV2-Lys47 with different forms of thrombin on the concentration of the
substrate tos-Gly-Pro-Lys-pNA. Assays were performed in PIPES-NaOH
buffer (Buffer 2) with thrombin from Sigma (A) or a-thrombin containing
4% 7-thrombin (B) and the data analysed according to equation (1) to yield
estimates for Ky at the indicated substrate concentrations. For the data in
(B) the estimates of Kv were weighted according to the squared inverse of
their standard errors and fitted to equation (6). The line drawn depicts the
result of this fitting with the value of Km fixed at 105 pM.
be directly comparable with those of Degryse et al. (1989).
However, Tris-HCl buffers have a much better buffering
capacity at the pH values used (Ellis and Morrison, 1982).] In
Tris-HCl buffer with an ionic strength of 0.325 M (Buffer 3),
a Kx value of 2.47 ± 0.04 pM was determined for rHV2-Lys47
(Table I). This value agrees well with those determined in the
PIPES -NaOH buffer (Buffer 2) which has about the same ionic
strength. Under the same conditions, a value of 0.99 ± 0.03 pM
was determined for the K{ of rHVl (Table I). The association
rate constants (&,) for rHVl and rHV2-Lys47 were about equal
and, thus, the increase in the affinity observed with rHVl can
be attributed to a lower rate of dissociation of rHV 1 from the
hirudin—thrombin complex (Table I).
In Tris-HCl buffer with an ionic strength of 0.125 M
(Buffer 1), the difference between the K{ values for rHVl and
rHV2-Lys47 was slightly less; values of 0.231 ± 0.006 and
0.364 ± 0.015 pM were observed for rHVl and rHV2-Lys47
respectively (Table I). Once again, the kl values for both forms
were about equal. The values of k} and K\ for both rHVl and
rHV2-Lys47 were lower at the lower ionic strength in
accordance with previous observations (Stone and Hofsteenge,
1986; Stone etal, 1989).
Effect of the presence of y-thrombin in preparations used for
kinetics
The results shown in Figures 1 and 2 contrast with those obtained
by Degryse et al. (1989), where a hyperbolic dependence of Kv
on substrate concentration was observed. Such a hyperbolic
dependence suggests a noncompetitive mechanism for the
inhibition of thrombin by hirudin. It seemed possible that the
difference between the results obtained by Degryse et al. (1989)
and those of the present study could be due to the different forms
of thrombin used in the two studies. In order to test this
possibility, K\< values were determined under the conditions
used by Degryse etal. (1989) with commercial human a-
thrombin from the same source; i.e. Buffer 2 and tos-Gly-Pro-
Lys-pNA with 4.5 nM human thrombin from Sigma and 0—6 nM
rHV2-Lys47. The substrate dependence of the Kv value
determined under these conditions is shown in Figure 3(A). The
values of Kv determined using this source of thrombin were
much higher than the values at corresponding substrate
concentrations shown in Figure 1. Moreover, the almost
negligible substrate dependence of the Kv values suggests
Fig. 4. Comparison of the binding of rHV2-Lys47 and D-Phe-Pro-ArgCH2 to the active-site of thrombin. The binding of rHV2-Lys47 (thick lines: from Rydel
et al., 1990) to the active site of human a-thrombin is compared with that of D-Phe-Pro-ArgCH2 (dotted lines; from Bode et al., 1989)
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uncompetitive inhibition. The results of Figure 3 also differ
somewhat from those obtained by Degryse et al. (1989)
suggesting that there may be some batch-to-batch variation in
the kinetic behaviour of commercial thrombin preparations.
Human /3- and 7-thrombin can arise by autolytic degradation of
a-thrombin (Fenton et al., 1977a,b) and it has been shown
previously that 13- and 7-thrombin have a much lower affinity
for hirudin than a-thrombin (Landis et al., 1978; Stone et al.,
1987). PAGE of the Sigma thrombin used in the present study
indicated that it contained >20% degraded thrombin. The effect
of contamination with 7-thrombin was determined experimentally
by adding 7-thrombin to pure a-thrombin. The results obtained
when a-thrombin was contaminated with 4% 7-thrombin are
shown in Figure 3(B). These results are similar to those obtained
by Degryse et al. (1989); the hyperbolic dependence of Kv on
the substrate concentration suggests noncompetitive inhibition.
Equation (6) describes the dependence of Kv on substrate
concentration for a noncompetitive inhibitor:
_ Km + S
Kv
 ~
 ( 6KJKa S!KU
where Kih and Kn represent the dissociation constant of the
inhibitor from the free enzyme and the enzyme-substrate
complex respectively. Weighted nonlinear regression analysis of
the data of Figure 3(B) according to this equation yielded values
of 32 ± 1 and 86 ± 4 pM for Ka and Ku respectively. Degryse
et al. (1989) analysed their data according to equation (6) and
obtained values of 14 and 129 pM for KK and Ki{ respectively.
An alternative explanation for the different kinetic behaviour
observed with commercial thrombin is that it contains proteases
other than thrombin that are not inhibited by hirudin. Hirudin
demonstrates an absolute specificity for thrombin. All other
proteases so far examined are not inhibited even with micromolar
concentrations of hirudin (Wallis, 1988), while even the degraded
forms of thrombin will be completely inhibited by micromolar
concentrations. Under the conditions of the assay, rHVl has K\
values of 49 pM and 85 nM with /3- and 7-thrombin respectively
(S.R.Stone and J.Hofsteenge, unpublished results). The prepara-
tion of thrombin from Sigma used in this study was completely
inhibited by 1.6 /*M rHVl and, thus, a contamination by other
proteases is not the cause of the anomalous kinetic behaviour
observed with this preparation of thrombin.
The effect of contamination with degraded forms of thrombin,
specifically 7-thrombin, was further investigated by using data
simulation techniques. The Kx value for rHV2-Lys47 with 7-
thrombin required for these simulations was determined to be
75 ± 3 nM which is 104-fold higher than that observed with
a-thrombin. Using this value, data were simulated for various
percentage contaminations with 7-thrombin as described in
Materials and methods. Ten sets of data were simulated for
several substrate concentrations and these data were analysed
according to equation 1. The results obtained depended markedly
on the percentage contamination by 7-thrombin, the total enzyme
concentration and the range of hirudin concentrations used. The
deviation of the results from those expected for a competitive
inhibitor was smaller with lower contaminations of 7-thrombin,
with lower total enzyme concentrations and with ranges of
inhibitor concentrations that did not greatly exceed the
concentration of a-thrombin. Higher levels of contamination
(> 10%) together with high enzyme concentrations (> 1 nM) and
inhibitor to enzyme ratios (>2) led to data that suggested
uncompetitive inhibition and were similar to those shown in
Figure 3(A). Low contaminations of 7-thrombin (2-5%) yielded
data that were consistent with noncompetitive inhibition. The data
of Degryse et al. (1989) were best simulated by assuming a
contamination of 2% 7-thrombin. Simulations of the effect of
a contamination with /3-thrombin, assuming a K^ value of 50 pM
for rHV2-Lys47 with this form (see above), indicated that
preparations with a relatively large contamination (10%) of /3-
thrombin should still yield data consistent with competitive
inhibition but the observed values of the Kv would be increased.
Discussion
The results presented here indicate that rHV2-Lys47 is a
competitive inhibitor of human a-thrombin. The competitive
nature of the inhibition was demonstrated with two substrates
(Figures 1 and 2). Similar results have been obtained previously
for native hirudin variant-1 (Stone and Hofsteenge, 1986). These
results, however, contrast with those of Degryse et al. (1989);
these workers suggested a noncompetitive mechanism for the
inhibition of human a-thrombin by rHV2-Lys47. The discrep-
ancy between the two studies is due probably to the different
thrombin preparations used, as indicated by the data presented
in Figure 3. The data obtained in the present study with a
commercial thrombin preparation were also not consistent with
competitive inhibition (Figure 3A). The kinetic behaviour of the
commercial preparation is probably due to the presence of
degraded forms of thrombin (j3 and 7). It was shown experi-
mentally that a slight contamination of a-thrombin by 7-thrombin
(4%) can yield data suggesting noncompetitive inhibition
(Figure 3B). 7-Thrombin is a degraded form of a-thrombin that
can arise through autolysis (Fenton et al., 1977a,b). This form
of thrombin has a much reduced activity with fibrinogen (Lewis
etal, 1987) and its affinity for hirudin is likewise greatly
diminished (Landis et al., 1978; Stone et al., 1987). Simulations
of the effect of contaminating 7-thrombin on the determined Kv
value indicate that a contamination as low as 2 % could yield data
consistent with a noncompetitive mechanism. Larger contamina-
tions would yield data that suggest uncompetitive inhibition. These
results illustrate the importance of using pure a-thrombin
preparations for the determination of the kinetics of inhibition
with hirudin.
The recently determined crystal structures of thrombin—hirudin
complexes also indicate that hirudin inhibits thrombin by a
competitive mechanism (Grutter et al., 1990; Rydel et al., 1990).
The binding of rHV2-Lys47 (bold structure) and the substrate-
like inactivator D-Phe-Pro-Arg-CH2 (dotted structure) to the
active site of thrombin are contrasted in Figure 4. From this
figure, it is obvious that Del and Tyr3 of hirudin occupy the S2
and S3 sites of the substrate (nomenclature of Schechter and
Berger, 1967) and, thus, the binding of a tripeptidyl substrate
and hirudin would be mutually exclusive. In other words, the
structure illustrated in Figure 4 indicates that hirudin must be
a competitive inhibitor with respect to tripeptidyl p-nitroanilide
substrates as has been observed in the present study.
Although hirudin is a competitive inhibitor with respect to
tripeptidyl p-nitroanilide substrates, it also utilizes binding sites
on thrombin that are distant from the active site. The X-ray crystal
structures of thrombin-hirudin complexes show that the C-
terminal tail of hirudin makes numerous electrostatic and
hydrophobic contacts with a surface groove of thrombin (Grutter
et al., 1990; Rydel et al., 1990). It had been shown previously
that fragments of hirudin consisting of the C-terminal tail were
capable of binding to thrombin (Mao et al., 1988; Krstenansky
and Mao, 1987; Maraganore et al., 1989). Indeed, hirudin itself
is capable of binding to thrombin when its active site is occupied
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by a tripeptidyl inhibitor (Stone etai, 1987). The affinity of
thrombin for the C-terminaJ fragments of hirudin is, however,
about seven orders of magnitude lower than its affinity for hirudin
(Krstenansky and Mao, 1987; Braun et al., 1988a). Moreover,
the binding of the C-terminal fragment of hirudin to thrombin
does not inhibit the activity of thrombin with tripeptidyl substrates.
Indeed, the binding of C-terminal fragments of hirudin to
thrombin stimulates its activity with respect to small substrates
(Dennis etal, 1990; Naski etal, 1990).
The data presented in Table I indicate that rHVl and
rHV2-Lys47 have basically the same kinetic parameters for the
inhibition of human a-thrombin; rHVl has a slightly higher
affinity. The primary structures of rHV2-Lys47 and rHVl differ
from each other in eight of the 65 residues in the polypeptide
chain. Four of the differences between the two hirudins occur
in residues that do not make any contacts with thrombin (Asn33,
Lys35, Gly36 and Asn53 of rHV2-Lys47; Rydel et al., 1990).
The small difference in affinity between the two forms may be
due to differences in interactions between thrombin and one or
more of the other altered residues (Del, Thr2, Lys24 and Glu49
of rHV2-Lys47). Considering the similarity of the kinetic
parameters for rHVl and rHV2-Lys47, whose sequences are as
dissimilar as any two hirudin variants (Scharf et al., 1989), it
seems unlikely that the previously observed large variation in
dissociation constants is due to differences in the hirudin forms
used. Differences in reaction conditions, thrombin preparations
and/or methods of data analysis seem more likely to be the cause
of these discrepancies.
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